Gilead
Biotech

Gilead blames low infection rates for ending 2 RSV trials

Gilead has blamed the low rate of respiratory syncytial virus infections last season for ending two midstage trials of obeldesivir.
James Waldron Jun 27, 2025 4:09am
Collection of bright seamless colorful minimalistic patterns

Alphabet's Calico weaves anti-aging deal with China's Mabwell

Jun 26, 2025 4:52pm
An elderly persons face as viewed from the eyes up

Glaukos nets EU green lights for glaucoma surgery micro-stents

Jun 27, 2025 1:55pm
Law Legal System Justice Crime concept Mallet Gavel Hammer and Scales on tabl

Judge rejects CytoDyn's motion to dismiss investor lawsuit

Jun 27, 2025 11:53am
colorful brain art model

GE HealthCare's PET agent Vizamyl expands reach in Alzheimer's

Jun 27, 2025 9:45am
Three blocks displaying from left to right a person a handshake and another person

Turnstone, once allied with AbbVie, accepts $8M Xoma buyout

Jun 27, 2025 9:00am
More News

Incyte, FDA, Sun Pharma and more—Chutes & Ladders

Jun 27, 2025 8:30am
Fierce Pharma

Vor Bio's surprise $4B revival deal splits investor reactions

Jun 26, 2025 10:55am

FDA amplifies Medtronic recall of Bravo acid reflux test capsule

Jun 26, 2025 10:33am

Invivyd says Pemgarda sequel could be alternative to COVID shots

Jun 26, 2025 10:12am